Page last updated: 2024-12-08
pms 601
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
PMS 601: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 462383 |
| CHEMBL ID | 6322 |
| SCHEMBL ID | 7243345 |
| MeSH ID | M0365363 |
Synonyms (16)
| Synonym |
|---|
| diethyl-carbamic acid 1,4-bis-(3,4,5-trimethoxy-benzoyl)-piperazin-2-ylmethyl ester(pms 601) |
| diethyl-carbamic acid 1,4-bis-(3,4,5-trimethoxy-benzoyl)-piperazin-2-ylmethyl ester |
| bdbm50046993 |
| pms-601 |
| 158978-98-4 |
| pms 601 |
| [1,4-bis(3,4,5-trimethoxybenzoyl)piperazin-2-yl]methyl n,n-diethylcarbamate |
| carbamic acid, n,n-diethyl-, [1,4-bis(3,4,5-trimethoxybenzoyl)-2-piperazinyl]methyl ester |
| CHEMBL6322 , |
| ZINC04394014 |
| carbamic acid, n,n-diethyl-, (1,4-bis(3,4,5-trimethoxybenzoyl)-2-piperazinyl)methyl ester |
| 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-(n,n-diethylaminocarbonyloxymethyl)piperazine |
| QKSXEJNMSRTCRE-UHFFFAOYSA-N |
| SCHEMBL7243345 |
| DTXSID30936025 |
| [1,4-bis(3,4,5-trimethoxybenzoyl)piperazin-2-yl]methyl diethylcarbamate |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The transport parameter measured (K(in)) proves that 1a is able to cross this biological barrier, but a pharmacokinetic study reveals its weak bioavailability in rats." | ( Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity. Bensaid, O; Cisternino, S; Clayette, P; Dereuddre-Bosquet, N; Dong, CZ; Dormont, D; Heymans, F; Huet, J; Lamouri, A; Martin, M; Redeuilh, C; Rousselle, C; Scherrmann, JM; Serradji, N, 2004) | 0.32 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Platelet-activating factor receptor | Cavia porcellus (domestic guinea pig) | IC50 (µMol) | 25.8000 | 0.0043 | 0.7577 | 7.8000 | AID167654 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (16)
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 23.95
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.95) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||